MiMedx Group, Inc. Stock price

Equities

MDXG

US6024961012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
8.63 USD +5.76% Intraday chart for MiMedx Group, Inc. +5.23% -1.61%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 358M Sales 2025 * 404M Capitalization 1B
Net income 2024 * 44M Net income 2025 * 56M EV / Sales 2024 * 2.81 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.49 x
P/E ratio 2024 *
27.6 x
P/E ratio 2025 *
21.7 x
Employees 867
Yield 2024 *
-
Yield 2025 *
-
Free-Float 56.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.75%
1 week+5.23%
Current month+5.75%
1 month+9.51%
3 months+8.00%
6 months+12.36%
Current year-1.61%
More quotes
1 week
8.06
Extreme 8.06
9.04
1 month
7.61
Extreme 7.61
9.04
Current year
7.61
Extreme 7.61
9.04
1 year
3.08
Extreme 3.08
9.27
3 years
2.43
Extreme 2.43
15.99
5 years
2.28
Extreme 2.28
15.99
10 years
0.95
Extreme 0.95
18.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 23-01-26
Director of Finance/CFO 58 23-07-04
Chief Tech/Sci/R&D Officer - 21-05-31
Members of the board TitleAgeSince
Director/Board Member 70 20-07-01
Director/Board Member 73 21-03-07
Director/Board Member 61 19-06-18
More insiders
Date Price Change Volume
24-03-01 8.63 +5.76% 1,695,131
24-02-29 8.16 -0.49% 2,090,623
24-02-28 8.2 -2.38% 779,527
24-02-27 8.4 +1.69% 790,971
24-02-26 8.26 +0.73% 598,765

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. The Company is focused on addressing unmet clinical needs in the areas of Advanced Wound Care, Surgical Recovery, and osteoarthritis. The Company operates through two segments: Wound and Surgical, and Regenerative Medicine. The Wound and Surgical segment focuses on the Advanced Wound Care and Surgical Recovery markets. Its platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc. The Regenerative Medicine segment focuses solely on Regenerative Medicine technologies. The Company's product portfolio and pipeline include EPIFIX, AMNIOFIX, mDHACM, AMNIOBURN, EPICORD and AMNIOCORD, AXIOFILL, and AMNIOEFFECT.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.63 USD
Average target price
12.52 USD
Spread / Average Target
+45.12%
Consensus
  1. Stock
  2. Equities
  3. Stock MiMedx Group, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW